ACQUIRED ANGIOEDEMA TYPE-II (AAE-II) - MECHANISM OF ACTION OF AN AUTOANTIBODY DIRECTED AGAINST C1-ESTERASE INHIBITOR (CIEI)

被引：0
|
作者：
MALBRAN, A [1 ]
HAMMER, C [1 ]
FRANK, MM [1 ]
FRIES, L [1 ]
机构：
[1] NIAID,CLIN INVEST LAB,BETHESDA,MD 20205
来源：
CLINICAL RESEARCH | 1987年 / 35卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：A255 / A255
页数：1
相关论文
共 39 条
  • [31] Treatment of hereditary angioedema with human C1 esterase inhibitor: results of a global, multicenter, randomized, placebo-controlled, phase II/III dose finding study (IMPACT1)
    Kiessling, P. K.
    Craig, T.
    Levy, R.
    Wasserman, R. L.
    Bewtra, A. K.
    Hurewitz, D.
    Obtulowicz, K.
    Reshef, A.
    Ritchie, B.
    Moldovan, D.
    Shirov, T.
    Grivcheva-Panovska, V
    Kiessling, P. C.
    Bernstein, J.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2008, 154 : 143 - 144
  • [32] Evaluation of a 5-weight-band dosing strategy for icatibant in pediatric patients with hereditary angioedema with C1-inhibitor deficiency type I/II
    Farkas, H.
    Vardi, M.
    Wang, Y.
    ALLERGY, 2018, 73 : 719 - 720
  • [33] The dominant form of the C1 inhibitor R444C variant causing type II hereditary angioedema is its covalent adduct with serum albumin explaining elevated levels
    Farkas, Bence
    Gal, Peter
    Varga, Lilian
    Farkas, Henriette
    Dobo, Jozsef
    IMMUNOBIOLOGY, 2023, 228 (05) : 71 - 72
  • [34] Treatment of acute abdominal and facial attacks of hereditary angioedema (HAE) with human C1 esterase inhibitor (C1-INH): Results of a global, multicenter, randomized, placebo-controlled, phase II/III study (IMPACT1)
    Bernstein, J. A.
    Levy, R.
    Wasserman, R. L.
    Bewtra, A.
    Hurewitz, D.
    Obtulowicz, K.
    Reshef, A.
    Kiessling, P. C.
    Craig, T. J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (03) : 795 - 795
  • [35] TYPE-II HEREDITARY ANGIONEUROTIC-EDEMA THAT MAY RESULT FROM A SINGLE NUCLEOTIDE CHANGE IN THE CODON FOR ALANINE-436 IN THE C1 INHIBITOR GENE
    LEVY, NJ
    RAMESH, N
    CICARDI, M
    HARRISON, RA
    DAVIS, AE
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (01) : 265 - 268
  • [36] Characterization of Antibodies Directed against the Immunoglobulin Light κ Chain Variable Chain Region (VK) of Hepatitis C Virus-Related Type-II Mixed Cryoglobulinemia and B-Cell Proliferations
    de Re, Valli
    Simula, Maria Paola
    Pavan, Alessandro
    Garziera, Marica
    Marin, Dolores
    Dolcetti, Riccardo
    de Vita, Salvatore
    Sansonno, Domenico
    Geremia, Silvano
    Toffoli, Giuseppe
    CONTEMPORARY CHALLENGES IN AUTOIMMUNITY, 2009, 1173 : 152 - 160
  • [37] Treatment of hereditary angioedema with human C1 esterase inhibitor: results of a global, multicenter, randomised, placebo-controlled, phase II/III dose finding study of acute abdominal and facial attacks (IMPACT1)
    Craig, T.
    Levy, R.
    Wasserman, R.
    Bewtra, A.
    Hurewitz, D.
    Obtulowicz, K.
    Reshef, A.
    Kiessling, P.
    Bernstein, J.
    ALLERGY, 2008, 63 : 350 - 351
  • [38] DYSFUNCTIONAL C1BAR-INHIBITOR(AT), ISOLATED FROM A TYPE-II HEREDITARY-ANGIO-EDEMA PLASMA, CONTAINS A P1 REACTIVE CENTER (ARG-444-]HIS) MUTATION
    AULAK, KS
    PEMBERTON, PA
    ROSEN, FS
    CARRELL, RW
    LACHMANN, PJ
    HARRISON, RA
    BIOCHEMICAL JOURNAL, 1988, 253 (02) : 615 - 618
  • [39] EFFECTS OF THE ALPHA-GLUCOSIDASE INHIBITOR 1-DESOXYNOJIRIMYCIN (BAY M-1099) ON POSTPRANDIAL BLOOD-GLUCOSE, SERUM-INSULIN AND C-PEPTIDE LEVELS IN TYPE-II DIABETIC-PATIENTS
    SCHNACK, C
    ROGGLA, G
    LUGER, A
    SCHERNTHANER, G
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (04) : 417 - 419
1234